In fact, TNF-α inhibitors including etanercept and infliximab have been found to have antidepressant and cognitive-sparing effects in various neuroinflammation-based depressive syndrome and cognitive impairment in cancer patients, and their effect appears to result from a manner that focuses on the patho-physiology of depression rather than simply treating the symptoms. Here, TNF is linked to depressive symptom measurement.